Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tyrosine kinase inhibitors under investigation for the treatment of type II diabetes
Rana Malek, Stephen N. Davis
Expert Opinion on Investigational Drugs (2016) Vol. 25, Iss. 3, pp. 287-296
Closed Access | Times Cited: 21

Showing 21 citing articles:

Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 331-331
Open Access | Times Cited: 40
Effect of glycation inhibitors on aging and age-related diseases
Izabela Sadowska‐Bartosz, Grzegorz Bartosz
Mechanisms of Ageing and Development (2016) Vol. 160, pp. 1-18
Closed Access | Times Cited: 54
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
Rossella Mazzilli, Virginia Zamponi, Camilla Mancini, et al.
Endocrine (2025)
Closed Access
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia
Brittany M. Duggan, Kevin P. Foley, Brandyn D. Henriksbo, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 37
Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease
Lili Sheng, George Bayliss, Shougang Zhuang
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 26
Novel cancer therapies and their association with diabetes
Afreen Shariff, Sohail Syed, Rebecca A. Shelby, et al.
Journal of Molecular Endocrinology (2018) Vol. 62, Iss. 2, pp. R187-R199
Open Access | Times Cited: 31
Cardiac Metabolic Deregulation Induced by the Tyrosine Kinase Receptor Inhibitor Sunitinib is rescued by Endothelin Receptor Antagonism
Joevin Sourdon, Franck Lager, Thomas Viel, et al.
Theranostics (2017) Vol. 7, Iss. 11, pp. 2757-2774
Open Access | Times Cited: 28
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies
Zeng Wang, Liyu Jiang, Hao Yan, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 4, pp. 445-456
Closed Access | Times Cited: 14
The causal relationship between plasma protein‐to‐protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study
Yue‐Yang Zhang, Bingxue Chen, Qin Yang, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4410-4417
Closed Access | Times Cited: 1
Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
Rashmi R. Shah
Drug Safety (2016) Vol. 40, Iss. 3, pp. 211-228
Closed Access | Times Cited: 11
Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue
Zoltán Őrfi, Frigyes Wáczek, Ferenc Baska, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 8
Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis
Minglin Lin, Junfei Jin
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 5, pp. 268-268
Open Access | Times Cited: 7
Automated drug design of kinase inhibitors to treat Chronic Myeloid Leukemia
Aramice Y. S. Malkhasian, Brendan J. Howlin
Journal of Molecular Graphics and Modelling (2019) Vol. 91, pp. 52-60
Open Access | Times Cited: 7
The critical need for guidance in managing glycaemic control in patients with cancer
Edward L. Giovannucci
Diabetic Medicine (2021) Vol. 39, Iss. 1
Closed Access | Times Cited: 5
Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib
Bruno Martino, Corrado Mammì, Claudia Labate, et al.
Experimental Hematology (2017) Vol. 55, pp. 71-75
Open Access | Times Cited: 4
Effects of imatinib on glycemic and lipid profiles: a retrospective cohort study
Noa Markovits, Daniel Kurnik, Carmel Friedrich, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 9, pp. 2224-2232
Closed Access | Times Cited: 3
Effect of tyrosine kinase inhibitors on the glucose levels in diabetic and nondiabetic patients
Elena Yaiza Romero‐Ventosa, Luis Otero‐Millán, Sonia González‐Costas, et al.
Indian Journal of Cancer (2017) Vol. 54, Iss. 1, pp. 136-136
Closed Access | Times Cited: 2
Sorafenib decreases glycemia by impairing hepatic glucose metabolism
Jingjing Ma, Fang Sui, Yan Liu, et al.
Endocrine (2022) Vol. 78, Iss. 3, pp. 446-457
Closed Access | Times Cited: 2
Glucocorticoids and checkpoint tyrosine kinase inhibitors stimulate rat pancreatic beta cell proliferation differentially
Sarah Akbib, Jordy Stichelmans, Geert Stangé, et al.
PLoS ONE (2019) Vol. 14, Iss. 2, pp. e0212210-e0212210
Open Access | Times Cited: 1
The Potential of Sorafenib in Preventing Metabolic Syndrome in Rats Fed a High-Fat High-Sucrose Diet
Adnan Iqbal, Rahila Najam, Shabana Usman Sımjee, et al.
Journal of Hunan University Natural Sciences (2022) Vol. 49, Iss. 8, pp. 99-109
Open Access | Times Cited: 1
Activation of Discoidin Domain Receptors by collagen VI and collagen I fibrils
Despoina Gavriilidou
(2017)
Closed Access
Page 1

Scroll to top